Effective childhood cancer Treatment: the impact of large scale clinical trials in Germany and Austria
Standard
Effective childhood cancer Treatment: the impact of large scale clinical trials in Germany and Austria. / Rossig, C; Juergens, H; Schrappe, M; Moericke, A; Henze, G; von Stackelberg, A; Reinhardt, D; Burkhardt, B; Woessmann, W; Zimmermann, M; Gadner, H; Mann, G; Schellong, G; Mauz-Koerholz, C; Dirksen, U; Bielack, S; Berthold, F; Graf, N; Rutkowski, S; Calaminus, G; Kaatsch, P; Creutzig, U.
In: PEDIATR BLOOD CANCER, Vol. 60, No. 10, 01.10.2013, p. 1574-81.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Effective childhood cancer Treatment: the impact of large scale clinical trials in Germany and Austria
AU - Rossig, C
AU - Juergens, H
AU - Schrappe, M
AU - Moericke, A
AU - Henze, G
AU - von Stackelberg, A
AU - Reinhardt, D
AU - Burkhardt, B
AU - Woessmann, W
AU - Zimmermann, M
AU - Gadner, H
AU - Mann, G
AU - Schellong, G
AU - Mauz-Koerholz, C
AU - Dirksen, U
AU - Bielack, S
AU - Berthold, F
AU - Graf, N
AU - Rutkowski, S
AU - Calaminus, G
AU - Kaatsch, P
AU - Creutzig, U
N1 - Copyright © 2013 Wiley Periodicals, Inc.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from <20% before 1950 to >80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs and biologicals.
AB - In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from <20% before 1950 to >80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs and biologicals.
KW - Adolescent
KW - Austria
KW - Child
KW - Child, Preschool
KW - Clinical Trials as Topic
KW - Disease-Free Survival
KW - Female
KW - Germany
KW - History, 20th Century
KW - History, 21st Century
KW - Humans
KW - Infant
KW - Male
KW - Multicenter Studies as Topic
KW - Neoplasms
KW - Registries
KW - Survival Rate
U2 - 10.1002/pbc.24598
DO - 10.1002/pbc.24598
M3 - SCORING: Journal article
C2 - 23737479
VL - 60
SP - 1574
EP - 1581
JO - PEDIATR BLOOD CANCER
JF - PEDIATR BLOOD CANCER
SN - 1545-5009
IS - 10
ER -